Metastasic Prostate Cancer: Predictive Factors of Earlier Progression to Castration-Resistance.

Introduction: Prostate cancer (PCa) can progress to the lethal phenotype of metastatic castration resistance (mCRPC), either from initially localized disease or metastatic cancer. New drugs improving overall survival are now the cornerstone of treatment. Nevertheless, there are no defined sequences or established timing to initiate or discontinue treatments; besides, not all patients end in CRPC or reach this stage at the same time.

Damage Detection in Steel-Concrete Composite Structures by Impact Hammer Modal Testing and Experimental Validation.

Steel-concrete composite systems are an efficient alternative to mid- and high-rise building structures because of their high strength-to-weight ratio when compared to traditional concrete or steel constructive systems. Nevertheless, composite structural systems are susceptible to damage due to, for example, deficient construction processes, errors in design and detailing, steel corrosion, and the drying shrinkage of concrete. As a consequence, the overall strength of the structure may be significantly decreased.

Phononic Bandgap Optimization in Sandwich Panels Using Cellular Truss Cores.

The development of custom cellular materials has been driven by recent advances in additive manufacturing and structural topological optimization. These contemporary materials with complex topologies have better structural efficiency than traditional materials. Particularly, truss-like cellular structures exhibit considerable potential for application in lightweight structures owing to their excellent strength-to-mass ratio.

Enzalutamide as monotherapy for advanced prostate cancer: why not?

Objectives: Prostate cancer (PCa) is an androgen-dependent disease. In some cases, the tumor progresses despite castration levels of serum testosterone, turning into the lethal phenotype of castration-resistant prostate cancer (CRPC), still driven by androgens and requiring the androgen receptor as a driver and responsible for progression. Enzalutamide, an androgen receptor inhibitor, is indicated for the treatment of metastatic CRPC, asymptomatic or mildly symptomatic, after failure of androgen deprivation.

[Thrombosis of the portal vein as a complication of paroxysmal nocturnal hemoglobinuria].

A patient suffering nocturnal paroxysmal hemoglobinuria (HPN) associated with the recovery phase of a severe medullar aplasia, and who presented a thrombosis of the portal vein is described. The sudden appearance of fast growing splenomegaly with signs of hypersplenism was the sign that made us suspect of a portal thrombosis. The diagnosis was confirmed by an ultrasound and an angiographic study with DIVAS.